TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting

– Oral Presentation to Summarize Women’s Views on Vulvar and Vaginal
Atrophy –

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced that presentations related to its development
stage product candidates will be made at The North American Menopause
Society (NAMS) 2015 Annual Meeting taking place in Las Vegas on
September 30-October 3.

Sheryl A. Kingsberg, PhD, Chief of the Division of Behavioral Medicine
Department of OB/GYN at University Hospitals Case Medical Center in
Cleveland, will make an oral presentation titled “Women’s Attitudes and
Behaviors towards Vulvar and Vaginal Atrophy (VVA)” on Thursday, October
1 at 4:45 p.m. PDT.

TherapeuticsMD is currently developing TX-004HR (estradiol in VagiCap™),
an applicator-free vaginal estradiol product candidate for the treatment
of moderate to severe pain during sexual intercourse (dyspareunia), a
symptom of VVA due to menopause. TX-004HR is being evaluated in a
fully-enrolled phase 3 clinical trial, known as the REJOICE Trial.
TherapeuticsMD currently anticipates that the topline results from the
Rejoice Trial will be reported during the fourth quarter of 2015.

In addition, two scientific posters related to TherapeuticsMD
preclinical transdermal progesterone program will be presented at a
session on Thursday, October 1 at 6:00 p.m. PDT.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
patented SYMBODA™ technology, TherapeuticsMD is developing advanced
hormone therapy pharmaceutical products to enable delivery of
bio-identical hormones through a variety of dosage forms and
administration routes. The company’s clinical development pipeline
includes two phase 3 products. The company also manufactures and
distributes branded and generic prescription prenatal vitamins as well
as over-the-counter vitamins under vitaMedMD^® and BocaGreenMD^®
brands. More information is available at the following websites: www.therapeuticsmd.com,
www.vitamedmd.com,
www.vitamedmdrx.com,
and www.bocagreenmd.com.

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

Contacts

TherapeuticsMD, Inc.
Dan Cartwright, 561-961-1900
Chief
Financial Officer
Dan.Cartwright@TherapeuticsMD.com